#United States #Jersey City #Bronchiectasis #Synchrony Medical #LibAirty™

Synchrony Medical Initiates Groundbreaking Study on LibAirty™ System

Synchrony Medical, a pioneering company in respiratory care technology based in Jersey City, New Jersey, has announced the commencement of a vital study titled RELACS (Real Life Evaluation of the LibAirty™ Airway Clearance System in Adults with Bronchiectasis). This 12-month observational study aims to explore the clinical impacts of the FDA-cleared LibAirty™ system, specifically designed for airway clearance, among bronchiectasis patients.

What is Bronchiectasis?

Bronchiectasis is a chronic respiratory condition that results from the permanent widening and damage of the airways, leading to the accumulation of mucus. This condition is characterized by recurrent infections, persistent cough, and a gradual decline in lung functionality. Patients living with bronchiectasis face a continual struggle to manage their symptoms, often relying on daily airway clearance techniques to improve their quality of life and prevent disease progression.

The LibAirty™ Airway Clearance System

The LibAirty™ Airway Clearance System stands out due to its ease of use and clinical effectiveness. Utilizing principles of autogenic drainage, it allows patients to perform airway clearance therapy in the comfort of their homes. The device not only provides targeted chest pressure but also includes app-guided breathing coaching, making it straightforward for users to follow. Prior clinical trials conducted at the Sheba Medical Center and the Medical University of South Carolina indicated that users of LibAirty™ could clear twice the amount of sputum compared to conventional vest-based therapies while also reporting higher satisfaction levels.

The RELACS Study

The RELACS study is taking place in several prominent U.S. respiratory centers, including the Medical University of South Carolina, University of Alabama at Birmingham, and Emory University School of Medicine's Pulmonary Clinic in Atlanta. By enrolling bronchiectasis patients, the study aims to assess how the integration of LibAirty™ into their daily routines impacts health outcomes and overall quality of life, comparing findings with each participant's prior 12 months of medical history.

Dr. Patrick Flume, the Director of the Adult Cystic Fibrosis Center at MUSC Health, underscores the necessity of daily airway clearance for those suffering from bronchiectasis. He notes a positive response from patients since using LibAirty™, stating that many have reported significant improvements not just in lung clearance but also in comfort and convenience. The RELACS study seeks to capture these patient experiences to evaluate long-term clinical outcomes throughout the year-long study period.

Empowering Patients

According to Anat Shani, Co-Founder and CEO of Synchrony Medical, the LibAirty™ system was designed to empower individuals managing chronic lung conditions by facilitating independent health management at home. The RELACS study, advancing at leading respiratory centers, plays a crucial role in validating evidence-based, patient-focused technology.

Looking Ahead

The results of the RELACS study could pave the way for broader clinical acceptance and utilization of innovative technologies in the treatment of bronchiectasis and possibly in other chronic lung diseases. As this field advances, Synchrony Medical remains committed to improving patient outcomes through the development and implementation of effective airway clearance therapies.

For more detailed information about the RELACS study or to participate, interested individuals can visit ClinicalTrials.gov and look for Identifier NCT07135284. This initiative is an important step towards enhancing the lives of those affected by bronchiectasis and reinforcing the significance of ongoing research in respiratory health.